Literature DB >> 22698810

Splicing of phenylalanine hydroxylase (PAH) exon 11 is vulnerable: molecular pathology of mutations in PAH exon 11.

Caroline Heintz1, Steven F Dobrowolski, Henriette Skovgaard Andersen, Mübeccel Demirkol, Nenad Blau, Brage Storstein Andresen.   

Abstract

In about 20-30% of phenylketonuria (PKU) patients, phenylalanine (Phe) levels can be controlled by cofactor 6R-tetrahydrobiopterin (BH(4)) administration. The phenylalanine hydroxylase (PAH) genotype has a predictive value concerning BH(4)-response and therefore a correct assessment of the mutation molecular pathology is important. Mutations that disturb the splicing of exons (e.g. interplay between splice site strength and regulatory sequences like exon splicing enhancers (ESEs)/exon splicing silencers (ESSs)) may cause different severity of PKU. In this study, we identified PAH exon 11 as a vulnerable exon and used patient derived lymphoblast cell lines and PAH minigenes to study the molecular defect that impacted pre-mRNA processing. We showed that the c.1144T>C and c.1066-3C>T mutations cause exon 11 skipping, while the c.1139C>T mutation is neutral or slightly beneficial. The c.1144T>C mutation resides in a putative splicing enhancer motif and binding by splicing factors SF2/ASF, SRp20 and SRp40 is disturbed. Additional mutations in potential splicing factor binding sites contributed to elucidate the pathogenesis of mutations in PAH exon 11. We suggest that PAH exon 11 is vulnerable due to a weak 3' splice site and that this makes exon 11 inclusion dependent on an ESE spanning position c.1144. Importantly, this implies that other mutations in exon 11 may affect splicing, since splicing is often determined by a fine balance between several positive and negative splicing regulatory elements distributed throughout the exon. Finally, we identified a pseudoexon in intron 11, which would have pathogenic consequences if activated by mutations or improved splicing conditions. Exonic mutations that disrupt splicing are unlikely to facilitate response to BH(4) and may lead to inconsistent genotype-phenotype correlations. Therefore, recognizing such mutations enhances our ability to predict the BH(4)-response.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22698810     DOI: 10.1016/j.ymgme.2012.05.013

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  9 in total

1.  Eleven novel SLC12A1 variants and an exonic mutation cause exon skipping in Bartter syndrome type I.

Authors:  Yue Han; Xiangzhong Zhao; Sai Wang; Cui Wang; Dongxu Tian; Yanhua Lang; Irene Bottillo; Xinsheng Wang; Leping Shao
Journal:  Endocrine       Date:  2019-02-21       Impact factor: 3.633

2.  Exonic mutations in the SLC12A3 gene cause exon skipping and premature termination in Gitelman syndrome.

Authors:  Yoichi Takeuchi; Eikan Mishima; Hisato Shima; Yasutoshi Akiyama; Chitose Suzuki; Takehiro Suzuki; Takayasu Kobayashi; Yoichi Suzuki; Tomohiro Nakayama; Yasuhiro Takeshima; Norma Vazquez; Sadayoshi Ito; Gerardo Gamba; Takaaki Abe
Journal:  J Am Soc Nephrol       Date:  2014-07-24       Impact factor: 10.121

Review 3.  Antisense mediated splicing modulation for inherited metabolic diseases: challenges for delivery.

Authors:  Belen Pérez; Lluisa Vilageliu; Daniel Grinberg; Lourdes R Desviat
Journal:  Nucleic Acid Ther       Date:  2014-02       Impact factor: 5.486

4.  Linking genotypes database with locus-specific database and genotype-phenotype correlation in phenylketonuria.

Authors:  Sarah Wettstein; Jarl Underhaug; Belen Perez; Brian D Marsden; Wyatt W Yue; Aurora Martinez; Nenad Blau
Journal:  Eur J Hum Genet       Date:  2014-06-18       Impact factor: 4.246

5.  Functional characterization of the spf/ash splicing variation in OTC deficiency of mice and man.

Authors:  Ana Rivera-Barahona; Rocío Sánchez-Alcudia; Hiu Man Viecelli; Veronique Rüfenacht; Belén Pérez; Magdalena Ugarte; Johannes Häberle; Beat Thöny; Lourdes Ruiz Desviat
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240

6.  Splice-shifting oligonucleotide (SSO) mediated blocking of an exonic splicing enhancer (ESE) created by the prevalent c.903+469T>C MTRR mutation corrects splicing and restores enzyme activity in patient cells.

Authors:  Bruno Palhais; Veronica S Præstegaard; Rugivan Sabaratnam; Thomas Koed Doktor; Seraina Lutz; Patricie Burda; Terttu Suormala; Matthias Baumgartner; Brian Fowler; Gitte Hoffmann Bruun; Henriette Skovgaard Andersen; Viktor Kožich; Brage Storstein Andresen
Journal:  Nucleic Acids Res       Date:  2015-04-15       Impact factor: 16.971

7.  Intronic PAH gene mutations cause a splicing defect by a novel mechanism involving U1snRNP binding downstream of the 5' splice site.

Authors:  Ainhoa Martínez-Pizarro; Maja Dembic; Belén Pérez; Brage S Andresen; Lourdes R Desviat
Journal:  PLoS Genet       Date:  2018-04-23       Impact factor: 5.917

8.  A sensitive assay system to test antisense oligonucleotides for splice suppression therapy in the mouse liver.

Authors:  Lorena Gallego-Villar; Hiu Man Viecelli; Belén Pérez; Cary O Harding; Magdalena Ugarte; Beat Thöny; Lourdes R Desviat
Journal:  Mol Ther Nucleic Acids       Date:  2014-09-16       Impact factor: 10.183

9.  Genotype-phenotype associations in French patients with phenylketonuria and importance of genotype for full assessment of tetrahydrobiopterin responsiveness.

Authors:  Elise Jeannesson-Thivisol; François Feillet; Céline Chéry; Pascal Perrin; Shyue-Fang Battaglia-Hsu; Bernard Herbeth; Aline Cano; Magalie Barth; Alain Fouilhoux; Karine Mention; François Labarthe; Jean-Baptiste Arnoux; François Maillot; Catherine Lenaerts; Cécile Dumesnil; Kathy Wagner; Daniel Terral; Pierre Broué; Loïc de Parscau; Claire Gay; Alice Kuster; Antoine Bédu; Gérard Besson; Delphine Lamireau; Sylvie Odent; Alice Masurel; Jean-Louis Guéant; Fares Namour
Journal:  Orphanet J Rare Dis       Date:  2015-12-15       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.